[Diabetes therapy with continuous insulin infusion by a portable pump: metabolic effects of short-term treatment and long-term results in problem patients]. 1982

G Schernthaner, and W Graninger, and W Kwasny, and R Prager, and C Otto

In the present study the influence of a near normoglycemic state induced by continuous insulin infusion on various factors possibly involved in the pathophysiology of late diabetic complications was studied in 9 insulin-dependent diabetics. The application of a two-week continuous intravenous insulin infusion (CIVII) resulted in a normalisation of lipoprotein- and apolipoprotein fractions, whereas the in vivo platelet function remained unchanged. The low-T3-syndrome associated with an insufficient metabolic control in diabetics disappeared under the CIVII-treatment. The long-term effect of subcutaneous insulin infusion (CSII) administered by portable pumps was evaluated in 14 diabetic patients with different clinical problems or complications. Although the metabolic control and the daily life conditions improved significantly in these patients, nevertheless the pump treatment should be restricted at the present time to diabetics, who cannot be sufficiently controlled by conventional insulin therapy.

UI MeSH Term Description Entries
D007263 Infusions, Parenteral The administration of liquid medication, nutrient, or other fluid through some other route than the alimentary canal, usually over minutes or hours, either by gravity flow or often by infusion pumping. Intra-Abdominal Infusions,Intraperitoneal Infusions,Parenteral Infusions,Peritoneal Infusions,Infusion, Intra-Abdominal,Infusion, Intraperitoneal,Infusion, Parenteral,Infusion, Peritoneal,Infusions, Intra-Abdominal,Infusions, Intraperitoneal,Infusions, Peritoneal,Intra Abdominal Infusions,Intra-Abdominal Infusion,Intraperitoneal Infusion,Parenteral Infusion,Peritoneal Infusion
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D008075 Lipoproteins, HDL A class of lipoproteins of small size (4-13 nm) and dense (greater than 1.063 g/ml) particles. HDL lipoproteins, synthesized in the liver without a lipid core, accumulate cholesterol esters from peripheral tissues and transport them to the liver for re-utilization or elimination from the body (the reverse cholesterol transport). Their major protein component is APOLIPOPROTEIN A-I. HDL also shuttle APOLIPOPROTEINS C and APOLIPOPROTEINS E to and from triglyceride-rich lipoproteins during their catabolism. HDL plasma level has been inversely correlated with the risk of cardiovascular diseases. High Density Lipoprotein,High-Density Lipoprotein,High-Density Lipoproteins,alpha-Lipoprotein,alpha-Lipoproteins,Heavy Lipoproteins,alpha-1 Lipoprotein,Density Lipoprotein, High,HDL Lipoproteins,High Density Lipoproteins,Lipoprotein, High Density,Lipoprotein, High-Density,Lipoproteins, Heavy,Lipoproteins, High-Density,alpha Lipoprotein,alpha Lipoproteins
D008076 Cholesterol, HDL Cholesterol which is contained in or bound to high-density lipoproteins (HDL), including CHOLESTEROL ESTERS and free cholesterol. High Density Lipoprotein Cholesterol,Cholesterol, HDL2,Cholesterol, HDL3,HDL Cholesterol,HDL(2) Cholesterol,HDL(3) Cholesterol,HDL2 Cholesterol,HDL3 Cholesterol,alpha-Lipoprotein Cholesterol,Cholesterol, alpha-Lipoprotein,alpha Lipoprotein Cholesterol
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010349 Patient Compliance Voluntary cooperation of the patient in following a prescribed regimen. Client Adherence,Client Compliance,Non-Adherent Patient,Patient Adherence,Patient Cooperation,Patient Noncompliance,Patient Non-Adherence,Patient Non-Compliance,Patient Nonadherence,Therapeutic Compliance,Treatment Compliance,Adherence, Client,Adherence, Patient,Client Compliances,Compliance, Client,Compliance, Patient,Compliance, Therapeutic,Compliance, Treatment,Cooperation, Patient,Non Adherent Patient,Non-Adherence, Patient,Non-Adherent Patients,Non-Compliance, Patient,Nonadherence, Patient,Noncompliance, Patient,Patient Non Adherence,Patient Non Compliance,Patient, Non-Adherent,Therapeutic Compliances,Treatment Compliances
D011788 Quality of Life A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral, social environment as well as health and disease. HRQOL,Health-Related Quality Of Life,Life Quality,Health Related Quality Of Life
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol

Related Publications

G Schernthaner, and W Graninger, and W Kwasny, and R Prager, and C Otto
April 1989, Polskie Archiwum Medycyny Wewnetrznej,
G Schernthaner, and W Graninger, and W Kwasny, and R Prager, and C Otto
July 2013, Diabetes technology & therapeutics,
G Schernthaner, and W Graninger, and W Kwasny, and R Prager, and C Otto
December 2013, Diabetes technology & therapeutics,
G Schernthaner, and W Graninger, and W Kwasny, and R Prager, and C Otto
November 1981, British medical journal (Clinical research ed.),
G Schernthaner, and W Graninger, and W Kwasny, and R Prager, and C Otto
January 1984, Archives francaises de pediatrie,
G Schernthaner, and W Graninger, and W Kwasny, and R Prager, and C Otto
March 1983, Medicina clinica,
G Schernthaner, and W Graninger, and W Kwasny, and R Prager, and C Otto
January 1980, Diabetes care,
G Schernthaner, and W Graninger, and W Kwasny, and R Prager, and C Otto
March 1982, Deutsche medizinische Wochenschrift (1946),
G Schernthaner, and W Graninger, and W Kwasny, and R Prager, and C Otto
April 1984, Orvosi hetilap,
G Schernthaner, and W Graninger, and W Kwasny, and R Prager, and C Otto
July 2006, Vojnosanitetski pregled,
Copied contents to your clipboard!